PARP-1/Proteasome-IN-1

• UNSPSC Description:

  PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. PARP-1/Proteasome-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis[1].

• Target Antigen:

  Apoptosis; PARP; Proteasome

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/parp-1-proteasome-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CCSC)C(N[C@H](B1O[C@@](C[C@H]2C(C)(C)[C@@H]3C2)(C)[C@@]3([H])O1)CC(C)C)=O)C4=CC(CC5=NNC(C6=C5C=CC=C6)=O)=CC=C4F

• Molecular Weight:

  676.65

• References & Citations:

  [1]He H et al. Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer[J]. European Journal of Medicinal Chemistry, 2023: 115943.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported